Nuwellis, INC 8-K filings

Nuwellis, Inc. held a special meeting where stockholders approved the issuance of shares related to warrant exercises and a reverse stock split to meet Nasdaq listing requirements.

Nuwellis, Inc. announced the successful closing of its registered public offering, raising approximately $6.0 million in gross proceeds.

Nuwellis, Inc. announced its first quarter 2026 financial results, reporting a 26% increase in net sales to $2.4 million and improved gross margin to 70.1%.

Nuwellis, Inc. held its annual meeting on April 28, 2026, where stockholders elected two Class I directors and ratified Baker Tilly US, LLP as the independent auditor for fiscal year 2026.

Nuwellis, Inc. has reached a settlement agreement to resolve a breach of contract lawsuit filed by E.F. Hutton & Co.

Nuwellis, Inc. filed an amended 8-K to include response letters from two former directors who dispute the company's characterization of their resignations.

Two independent directors of Nuwellis, Inc. resigned, citing significant disagreements over corporate governance, information access, and management conduct.

Nuwellis, Inc. announced the closing of its acquisition of Israeli-based Rendiatech, Inc., a developer of automated kidney function monitoring technology.

Nuwellis, Inc. announced two new independent director appointments and disclosed a lawsuit filed by E.F. Hutton & Co.

Nuwellis, Inc. announced a $5 million capital raise through a private placement and warrant inducement, the strategic acquisition of Rendiatech Ltd. for renal monitoring technology, and the appointment of Carisa Schultz as its new Chief Financial Officer.

Nuwellis, Inc. announced significant changes to its board of directors, including three resignations and the appointment of two new independent directors, effective January 21, 2026.

Nuwellis, Inc. reported third quarter 2025 financial results with total revenue of $2.2 million, a 6% year-over-year decrease, while advancing its U.S.-focused cardiorenal growth strategy.

Nuwellis, Inc. announced the resignation of its Chief Financial Officer, Robert B. Scott, and the appointment of President and CEO John L. Erb as interim CFO.

Nuwellis, Inc. announced findings from its ULTRA-Peds registry, an observational study on the Aquadex System's use in children with kidney conditions.

Nuwellis, Inc. announced the issuance of a U.S. patent for hemolysis sensors in extracorporeal blood filtration systems, supporting its pediatric device Vivian.

Nuwellis, Inc.'s development partner, Koronis Biomedical Technologies, has been awarded an approximately $3 million multi-year grant from the National Institutes of Health to accelerate the Vivian pediatric CRRT device and enhance core software.

Nuwellis, Inc. has entered into an At The Market Offering Agreement to sell up to $4.65 million of its common stock through Ladenburg Thalmann & Co. Inc. to raise capital.

Nuwellis, Inc. announced FDA 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter, expanding its product offering.

Nuwellis, Inc. announced a non-binding letter of intent to acquire Israeli medical device company Rendiatech, Ltd., specializing in real-time urine flow and acute kidney injury monitoring.

Nuwellis, Inc. reported a decline in second-quarter 2025 revenue to $1.7 million, primarily due to an industry-wide sterilization delay, while expanding its pediatric market presence and completing a $5 million capital raise.

Nuwellis, Inc. stockholders approved proposals for a reverse stock split, increased authorized shares, and warrant share issuance at a special meeting.

Nuwellis, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, leading to the cancellation of its delisting hearing and continued listing on The Nasdaq Capital Market.

Nuwellis, Inc. announced the permanent appointment of John L. Erb as Chief Executive Officer and President, alongside the execution of a 1-for-42 reverse stock split to maintain Nasdaq listing compliance.

Nuwellis, Inc. received a delisting notice from Nasdaq due to its common stock trading below $1.00 for 30 consecutive days and plans to effect a reverse stock split to regain compliance.

Nuwellis, Inc. has filed a Certificate of Designation for new Series F-1 Convertible Preferred Stock and entered into an exchange agreement with CEO John L. Erb, converting his existing Series F shares into the new class, which includes a 19.99% beneficial ownership limitation, in anticipation of a future public offering.

Nuwellis, Inc. held its annual meeting on May 20, 2025, where stockholders approved the election of directors, a reverse stock split, and the ratification of the company's accounting firm.

Nuwellis, Inc. announced its first quarter 2025 financial results, showcasing growth in pediatric revenue and a significant reduction in operating expenses.

Nuwellis, Inc. has entered into a three-year supply agreement with Kluge Design, LLC for the manufacture and servicing of its Aquadex product line, effective May 9, 2025.

Nuwellis, Inc. is strategically realigning its focus towards critical care, pediatrics, and outpatient services, driven by increased reimbursement rates for its Aquadex system and promising clinical trial data.

Nuwellis, Inc. announced its Q4 and full-year 2024 financial results, highlighting a CMS payment increase and a 21% growth in consumables utilization despite a revenue decrease.